(Q38067255)

28 August 2017

1 reference

title

Synthetic immunostimulatory oligonucleotides in experimental and clinical practice (English)

1 reference

28 August 2017

Paweł Bodera

1

1 reference

28 August 2017

Wanda Stankiewicz

series ordinal

2

1 reference

28 August 2017

Janusz Kocik

series ordinal

3

1 reference

28 August 2017

publication date

1 January 2012

1 reference

28 August 2017

published in

Pharmacological Reports

1 reference

28 August 2017

volume

64

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

1003-1010

1 reference

Pathogen recognition and innate immunity

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

shRNA expression constructs designed directly from siRNA oligonucleotide sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

The immunostimulatory activity of unmethylated and methylated CpG oligodeoxynucleotide is dependent on their ability to colocalize with TLR9 in late endosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

TLR ligands in the local treatment of established intracerebral murine gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Patterns of oligonucleotide sequences in viral and host cell RNA identify mediators of the host innate immune system

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Oligonucleotide motifs that disappear during the evolution of influenza virus in humans increase alpha interferon secretion by plasmacytoid dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Fujita-Ban QSAR analysis and CoMFA study of quinoline antagonists of immunostimulatory CpG-oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

The sweetness of the DNA backbone drives Toll-like receptor 9.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Telomerase RNA inhibition using antisense oligonucleotide against human telomerase RNA linked to a 2',5'-oligoadenylate

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

Enhancement of radiosensitivity by CpG-oligodeoxyribonucleotide-7909 in human non-small cell lung cancer A549 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2812%2970899-X

7 January 2021

10.1016/S1734-1140(12)70899-X

Identifiers

DOI

1 reference

28 August 2017

1 reference